#BEGIN_DRUGCARD DB00968

# AHFS_Codes:
24:08.16

# ATC_Codes:
C02AB01
C02AB02

# Absorption:
Absorption from the gastrointestinal tract is variable but averages approximately 50%.

# Biotransformation:
Hepatic, extensively metabolized. The known urinary metabolites are: a-methyldopa mono-0-sulfate; 3-0-methyl-a-methyldopa; 3,4-dihydroxyphenylacetone; a-methyldopamine; 3-0-methyl-a-methyldopamine and their conjugates.

# Brand_Mixtures:
Aldoclor (Chlorothiazide + Methyldopa)
Aldoril (Hydrochlorothiazide + Methyldopa)
Apo Methazide (Hydrochlorothiazide + Methyldopa)
Novo-Doparil (Hydrochlorothiazide + Methyldopa)
PMS-Dopazide (Hydrochlorothiazide + Methyldopa)
Supres (Chlorothiazide + Methyldopa)

# Brand_Names:
Aldomet
Aldometil
Aldomin
Aldoril
Baypresol
Becanta
Dopamet
Dopatec
Dopegyt
Grospisk
Hyperpax
Hypolag
Medomet
Medopa
Medopal
Medopren
Methoplain
Novomedopa
Nu-Medopa
Presinol
Presolisin
Sedometil
Sembrina

# CAS_Registry_Number:
555-30-6

# ChEBI_ID:
61058

# Chemical_Formula:
C10H13NO4

# Chemical_IUPAC_Name:
(2S)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
426830

# Description:
An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent. [PubChem]

# Dosage_Forms:
Tablet	Oral

# Drug_Category:
Adrenergic alpha-Agonists
Antihypertensive Agents
Sympatholytics

# Drug_Interactions:
Carteolol	Possible hypertensive crisis
Dobutamine	Increased arterial pressure
Dopamine	Increased arterial pressure
Entacapone	Entacapone may increase the effect and toxicity of the sympathomimetic, methyldopa.
Ephedra	Increased arterial pressure
Ephedrine	Increased arterial pressure
Epinephrine	Increased arterial pressure
Fenoterol	Increased arterial pressure
Haloperidol	Methyldopa increases haloperidol effect or risk of psychosis
Iron	Iron decreases the absorption of dopa derivatives
Iron Dextran	Iron decreases the absorption of dopa derivatives
Isoproterenol	Increased arterial pressure
Levodopa	Methyldopa increases the effect and toxicity of levodopa
Lithium	Methyldopa may increase the adverse effects of lithium without affecting lithium serum levels. Monitor for signs and symptoms of lithium toxicity during concomitant therapy.
Mephentermine	Increased arterial pressure
Metaraminol	Increased arterial pressure
Methoxamine	Increased arterial pressure
Nadolol	Possible hypertensive crisis
Norepinephrine	Increased arterial pressure
Orciprenaline	Increased arterial pressure
Oxprenolol	Possible hypertensive crisis
Penbutolol	Possible hypertensive crisis
Phenylephrine	Increased arterial pressure
Phenylpropanolamine	Increased arterial pressure
Pindolol	Possible hypertensive crisis
Pirbuterol	Increased arterial pressure
Procaterol	Increased arterial pressure
Propranolol	Possible hypertensive crisis
Pseudoephedrine	Increased arterial pressure
Salbutamol	Increased arterial pressure
Sotalol	Possible hypertensive crisis
Terbutaline	Increased arterial pressure
Timolol	Possible hypertensive crisis
Tranylcypromine	The MAO inhibitor, Tranylcypromine, may increase the adverse effects of Methyldopa. Concomitant therapy is contraindicated.

# Drug_Reference:
12082488	Rosenthal T, Oparil S: The effect of antihypertensive drugs on the fetus. J Hum Hypertens. 2002 May;16(5):293-8.
1363322	van Zwieten PA: Development and trends in the drug treatment of essential hypertension. J Hypertens Suppl. 1992 Dec;10(7):S1-12.
17485976	Sica DA: Centrally acting antihypertensive agents: an update. J Clin Hypertens (Greenwich). 2007 May;9(5):399-405.
19202042	McCoy S, Baldwin K: Pharmacotherapeutic options for the treatment of preeclampsia. Am J Health Syst Pharm. 2009 Feb 15;66(4):337-44.
19821316	Mah GT, Tejani AM, Musini VM: Methyldopa for primary hypertension. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD003893.
6104975	van Zwieten PA: Pharmacology of centrally acting hypotensive drugs. Br J Clin Pharmacol. 1980;10 Suppl 1:13S-20S.
6295709	van Zwieten PA, Timmermans PB: Pharmacology and characterization of central alpha-adrenoceptors involved in the effect of centrally acting antihypertensive drugs. Chest. 1983 Feb;83(2 Suppl):340-3.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-1.7

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
1E+004 mg/L (at 25 °C)

# Food_Interactions:
Avoid alcohol.
Avoid natural licorice.
Increase dietary intake of magnesium, folate, vitamin B6, B12, and/or consider taking a multivitamin.
May take Vitamin D.
No iron, zinc or fluoride within 2 hours of taking this medication.
Take without regard to meals.

# GenBank_ID:
Not Available

# Generic_Name:
Methyldopa

# HET_ID:
Not Available

# Half_Life:
The plasma half-life of methyldopa is 105 minutes.

# InChI_Identifier:
InChI=1S/C10H13NO4/c1-10(11,9(14)15)5-6-2-3-7(12)8(13)4-6/h2-4,12-13H,5,11H2,1H3,(H,14,15)/t10-/m0/s1

# InChI_Key:
InChIKey=CJCSPKMFHVPWAR-JTQLQIEISA-N

# Indication:
For use in the treatment of hypertension.

# KEGG_Compound_ID:
C07194

# KEGG_Drug_ID:
D08205

# LIMS_Drug_ID:
968

# Mechanism_Of_Action:
Although the mechanism of action has yet to be conclusively demonstrated, the resultant hypotensive effect is most likely due to the drug's action on the CNS. Methyldopa is converted into the metabolite, alpha-methylnorepinephrine, in the CNS, where it stimulates the central inhibitory alpha-adrenergic receptors, leading to a reduction in sympathetic tone, total peripheral resistance, and blood pressure. Reduction in plasma renin activity, as well as the inhibition of both central and peripheral norepinephrine and serotonine production may also contribute to the drug's antihypertensive effect, although this is not a major mechanism of action. This is done through the inhibition of the decarboxylation of dihydroxyphenylalanine (dopa)—the precursor of norepinephrine—and of 5-hydroxytryptophan (5-HTP)—the precursor of serotonin—in the CNS and in most peripheral tissues.

# Melting_Point:
300 dec °C

# Molecular_Weight_Avg:
211.2145

# Molecular_Weight_Mono:
211.084457909

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/ald1012.shtml

# Pathways:
Not Available

# PharmGKB_ID:
PA450453

# Pharmacology:
Methyldopa is an aromatic-amino-acid decarboxylase inhibitor in animals and in man. Only methyldopa, the <i>L</i>-isomer of alpha-methyldopa, has the ability to inhibit dopa decarboxylase and to deplete animal tissues of norepinephrine. In man the antihypertensive activity appears to be due solely to the L-isomer. About twice the dose of the racemate (DL-alpha-methyldopa) is required for equal antihypertensive effect. Methyldopa has no direct effect on cardiac function and usually does not reduce glomerular filtration rate, renal blood flow, or filtration fraction. Cardiac output usually is maintained without cardiac acceleration. In some patients the heart rate is slowed. Normal or elevated plasma renin activity may decrease in the course of methyldopa therapy. Methyldopa reduces both supine and standing blood pressure. Methyldopa usually produces highly effective lowering of the supine pressure with infrequent symptomatic postural hypotension. Exercise hypotension and diurnal blood pressure variations rarely occur.

# Predicted_LogP_Hydrophobicity:
-2

# Predicted_LogS:
-2

# Predicted_Water_Solubility:
2.26e+00 g/l

# Primary_Accession_No:
DB00968

# Protein_Binding:
Low (less than 20%).

# PubChem_Compound_ID:
38853

# PubChem_Substance_ID:
46508535

# RxList_Link:
http://www.rxlist.com/cgi/generic2/methyl.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD01106

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
C[C@](N)(CC1=CC(O)=C(O)C=C1)C(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
AMD
Alpha medopa
Alphamethyldopa
L-Methyl Dopa
α-methyl-L-dopa

# Synthesis_Reference:
Not Available

# Toxicity:
The oral LD<sub>50</sub> of methyldopa is greater than 1.5 g/kg in both the mouse and the rat. Symptoms of overdose include bloating, constipation, diarrhea, dizziness, extreme drowsiness, gas, light-headedness, nausea, severely low blood pressure, slow heartbeat, vomiting, and weakness.

# Update_Date:
2013-02-08 16:19:47 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Methyldopa

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
COMT

# Phase_1_Metabolizing_Enzyme_1_ID:
3810

# Phase_1_Metabolizing_Enzyme_1_Name:
Catechol O-methyltransferase

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Catechol O-methyltransferase
MPEAPPLLLAAVLLGLVLLVVLLLLLRHWGWGLCLIGWNEFILQPIHNLLMGDTKEQRIL
NHVLQHAEPGNAQSVLEAIDTYCEQKEWAMNVGDKKGKIVDAVIQEHQPSVLLELGAYCG
YSAVRMARLLSPGARLITIEINPDCAAITQRMVDFAGVKDKVTLVVGASQDIIPQLKKKY
DVDTLDMVFLDHWKDRYLPDTLLLEECGLLRKGTVLLADNVICPGAPDFLAHVRGSSCFE
CTHYQSFLEYREVVDGLEKAIYKGPGSEAGP

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P21964

# Drug_Target_1_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10415926	Head GA: Central imidazoline- and alpha 2-receptors involved in the cardiovascular actions of centrally acting antihypertensive agents. Ann N Y Acad Sci. 1999 Jun 21;881:279-86.
1363322	van Zwieten PA: Development and trends in the drug treatment of essential hypertension. J Hypertens Suppl. 1992 Dec;10(7):S1-12.
14557373	Velliquette RA, Ernsberger P: Contrasting metabolic effects of antihypertensive agents. J Pharmacol Exp Ther. 2003 Dec;307(3):1104-11. Epub 2003 Oct 13.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
17485976	Sica DA: Centrally acting antihypertensive agents: an update. J Clin Hypertens (Greenwich). 2007 May;9(5):399-405.
8743022	van Zwieten PA: New central mediators as targets of centrally acting antihypertensive drugs. Clin Exp Hypertens. 1996 Apr-May;18(3-4):291-303.
9284427	Kawasaki H: [Centrally acting sympathetic inhibitors for therapy of patients with hypertension] Nippon Rinsho. 1997 Aug;55(8):2081-5.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
ADRA2A

# Drug_Target_1_GenBank_ID_Gene:
M23533

# Drug_Target_1_GenBank_ID_Protein:
178196

# Drug_Target_1_GeneCard_ID:
ADRA2A

# Drug_Target_1_Gene_Name:
ADRA2A

# Drug_Target_1_Gene_Sequence:
>1353 bp
ATGGGCTCCCTGCAGCCGGACGCGGGCAACGCGAGCTGGAACGGGACCGAGGCGCCGGGG
GGCGGCGCCCGGGCCACCCCTTACTCCCTGCAGGTGACGCTGACGCTGGTGTGCCTGGCC
GGCCTGCTCATGCTGCTCACCGTGTTCGGCAACGTGCTCGTCATCATCGCCGTGTTCACG
AGCCGCGCGCTCAAGGCGCCCCAAAACCTCTTCCTGGTGTCTCTGGCCTCGGCCGACATC
CTGGTGGCCACGCTCGTCATCCCTTTCTCGCTGGCCAACGAGGTCATGGGCTACTGGTAC
TTCGGCAAGGCTTGGTGCGAGATCTACCTGGCGCTCGACGTGCTCTTCTGCACGTCGTCC
ATCGTGCACCTGTGCGCCATCAGCCTGGACCGCTACTGGTCCATCACACAGGCCATCGAG
TACAACCTGAAGCGCACGCCGCGCCGCATCAAGGCCATCATCATCACCGTGTGGGTCATC
TCGGCCGTCATCTCCTTCCCGCCGCTCATCTCCATCGAGAAGAAGGGCGGCGGCGGCGGC
CCGCAGCCGGCCGAGCCGCGCTGCGAGATCAACGACCAGAAGTGGTACGTCATCTCGTCG
TGCATCGGCTCCTTCTTCGCTCCCTGCCTCATCATGATCCTGGTCTACGTGCGCATCTAC
CAGATCGCCAAGCGTCGCACCCGCGTGCCACCCAGCCGCCGGGGTCCGGACGCCGTCGCC
GCGCCGCCGGGGGGCACCGAGCGCAGGCCCAACGGTCTGGGCCCCGAGCGCAGCGCGGGC
CCGGGGGGCGCAGAGGCCGAACCGCTGCCCACCCAGCTCAACGGCGCCCCTGGCGAGCCC
GCGCCGGCCGGGCCGCGCGACACCGACGCGCTGGACCTGGAGGAGAGCTCGTCTTCCGAC
CACGCCGAGCGGCCTCCAGGGCCCCGCAGACCCGAGCGCGGTCCCCGGGGCAAAGGCAAG
GCCCGAGCGAGCCAGGTGAAGCCGGGCGACAGCCTGCGCGGCGCGGGCCGGGGGCGACGG
GGATCGGGACGCCGGCTGCAGGGCCGGGGGAGGAGCGCGTCGGGGCTGCCAAGGCGTCGC
GCTGGCGCGGGCGGGCAGAACCGCGAGAAGCGCTTCACGTTCGTGCTGGCCGTGGTCATC
GGAGTGTTCGTGGTGTGCTGGTTCCCCTTCTTCTTCACCTACACGCTCACGGCCGTCGGG
TGCTCCGTGCCACGCACGCTCTTCAAATTCTTCTTCTGGTTCGGCTACTGCAACAGCTCG
TTGAACCCGGTCATCTACACCATCTTCAACCACGATTTCCGCCGCGCCTTCAAGAAGATC
CTCTGTCGGGGGGACAGGAAGCGGATCGTGTGA

# Drug_Target_1_General_Function:
Involved in alpha2-adrenergic receptor activity

# Drug_Target_1_General_References:
11888275	Chung DA, Zuiderweg ER, Fowler CB, Soyer OS, Mosberg HI, Neubig RR: NMR structure of the second intracellular loop of the alpha 2A adrenergic receptor: evidence for a novel cytoplasmic helix. Biochemistry. 2002 Mar 19;41(11):3596-604.
1678390	Suryanarayana S, Daunt DA, Von Zastrow M, Kobilka BK: A point mutation in the seventh hydrophobic domain of the alpha 2 adrenergic receptor increases its affinity for a family of beta receptor antagonists. J Biol Chem. 1991 Aug 15;266(23):15488-92.
1678850	Wang CD, Buck MA, Fraser CM: Site-directed mutagenesis of alpha 2A-adrenergic receptors: identification of amino acids involved in ligand binding and receptor activation by agonists. Mol Pharmacol. 1991 Aug;40(2):168-79.
1849485	Chhajlani V, Rangel N, Uhlen S, Wikberg JE: Identification of an additional gene belonging to the alpha 2 adrenergic receptor family in the human genome by PCR. FEBS Lett. 1991 Mar 25;280(2):241-4.
2170371	Guyer CA, Horstman DA, Wilson AL, Clark JD, Cragoe EJ Jr, Limbird LE: Cloning, sequencing, and expression of the gene encoding the porcine alpha 2-adrenergic receptor. Allosteric modulation by Na+, H+, and amiloride analogs. J Biol Chem. 1990 Oct 5;265(28):17307-17.
2568356	Fraser CM, Arakawa S, McCombie WR, Venter JC: Cloning, sequence analysis, and permanent expression of a human alpha 2-adrenergic receptor in Chinese hamster ovary cells. Evidence for independent pathways of receptor coupling to adenylate cyclase attenuation and activation. J Biol Chem. 1989 Jul 15;264(20):11754-61.
2823383	Kobilka BK, Matsui H, Kobilka TS, Yang-Feng TL, Francke U, Caron MG, Lefkowitz RJ, Regan JW: Cloning, sequencing, and expression of the gene coding for the human platelet alpha 2-adrenergic receptor. Science. 1987 Oct 30;238(4827):650-6.

# Drug_Target_1_HGNC_ID:
HGNC:281

# Drug_Target_1_HPRD_ID:
00078

# Drug_Target_1_ID:
318

# Drug_Target_1_Locus:
10q24-q26

# Drug_Target_1_Molecular_Weight:
48957

# Drug_Target_1_Name:
Alpha-2A adrenergic receptor

# Drug_Target_1_Number_of_Residues:
450

# Drug_Target_1_PDB_ID:
1HOF

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_1_Protein_Sequence:
>Alpha-2A adrenergic receptor
MGSLQPDAGNASWNGTEAPGGGARATPYSLQVTLTLVCLAGLLMLLTVFGNVLVIIAVFT
SRALKAPQNLFLVSLASADILVATLVIPFSLANEVMGYWYFGKAWCEIYLALDVLFCTSS
IVHLCAISLDRYWSITQAIEYNLKRTPRRIKAIIITVWVISAVISFPPLISIEKKGGGGG
PQPAEPRCEINDQKWYVISSCIGSFFAPCLIMILVYVRIYQIAKRRTRVPPSRRGPDAVA
APPGGTERRPNGLGPERSAGPGGAEAEPLPTQLNGAPGEPAPAGPRDTDALDLEESSSSD
HAERPPGPRRPERGPRGKGKARASQVKPGDSLPRRGPGATGIGTPAAGPGEERVGAAKAS
RWRGRQNREKRFTFVLAVVIGVFVVCWFPFFFTYTLTAVGCSVPRTLFKFFFWFGYCNSS
LNPVIYTIFNHDFRRAFKKILCRGDRKRIV

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Alpha-2 adrenergic receptors mediate the catecholamine- induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol

# Drug_Target_1_SwissProt_ID:
P08913

# Drug_Target_1_SwissProt_Name:
ADA2A_HUMAN

# Drug_Target_1_Synonyms:
Alpha-2 adrenergic receptor subtype C10
Alpha-2A adrenoceptor
Alpha-2A adrenoreceptor
Alpha-2AAR

# Drug_Target_1_Theoretical_pI:
10.20

# Drug_Target_1_Transmembrane_Regions:
34-59
71-96
107-129
150-173
193-217
375-399
407-430

#END_DRUGCARD DB00968
